Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Oral Health
Published in: BMC Oral Health 1/2014

Open Access 01-12-2014 | Research article

Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006–2007 and 2012–2013

Authors: Yoshiaki Kamikawa, Youichirou Mori, Tomohiro Nagayama, Junichi Fujisaki, Daisuke Hirabayashi, Ryoichi Sakamoto, Tomofumi Hamada, Kazumasa Sugihara

Published in: BMC Oral Health | Issue 1/2014

Login to get access

Abstract

Background

The isolation frequency and susceptibility to antifungal agents of oral Candida isolates from patients with oral candidiasis (OC) were compared between studies conducted in 2006–2007 and 2012–2013.

Methods

A total158 strains was isolated from 112 patients who visited Kagoshima University Hospital for the treatment of OC during the 14-month period from February 2012 and March 2013, and evaluated on the isolation frequency of each Candida strain and the susceptibility against antifungal drugs as compared to those evaluated in 2006–2007.

Results

There was a higher frequency of xerostomia as a chief complaint and of autoimmune disease in the 2012–2013 study than in the 2006–2007 study. More than 95% of Candida isolates were C. albicans and C. glabrata. In addition, the proportion of the latter increased from 12.3% in the 2006–2007 study to 23.4% in the 2012–2013 study, while the proportion of the former decreased from 86.2% to 72.8%, respectively. C. albicans was isolated in almost all patients, while C. glabrata was only isolated concomitantly with C. albicans. Minimal inhibitory concentrations (MICs) were not significantly different between groups with a few exceptions. Candida isolates, of which MICs surpassed break points, apparently increased for miconazole and itraconazole against C. glabrata in the 2012–2013 study, but this was not statistically significant. As a result, more cases of autoimmune disease, a greater number of C. glabrata isolates, and higher resistance to azoles were seen in the 2012–2013 study than in the 2006–2007 study.

Conclusion

These data indicate that with recent increases in C. glabrata infection, a causative fungus of OC, and in C. glabrata resistance to azoles, caution is needed in the selection of antifungal drugs for the treatment of OC.
Appendix
Available only for authorised users
Literature
1.
Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA: International surveillance of blood stream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and south america for the SENTRY program. The SENTRY participant group. J Clin Microbiol. 1997, 36: 1886-1889.
2.
Messer SA, Moet GJ, Kirby JT, Jones RN: Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and aspergillus spp.: report from the SENTRY antimicrobial surveillance program (2006 to 2007). J Clin Microbiol. 2009, 47: 1942-1946. 10.1128/JCM.02434-08.CrossRefPubMedPubMedCentral
3.
Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 2001, 33: 1529-1535. 10.1086/323401.CrossRefPubMed
4.
Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ, Smietana JM, DiNubile MJ, Sable CA: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002, 113: 294-299. 10.1016/S0002-9343(02)01191-9.CrossRefPubMed
5.
de Wet N, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF, Della Negra M, Diekmann-Berndt H: A randomized, double blind, parallel group, dose–response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV positive patients. Clin Infect Dis. 2004, 39: 842-8499. 10.1086/423377.CrossRefPubMed
6.
Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP, Aible M, Henkel T: A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004, 39: 770-775. 10.1086/423378.CrossRefPubMed
7.
Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S, the Japan invasive mycosis surveillance study group: National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother. 2004, 53: 283-289. 10.1093/jac/dkh053.CrossRefPubMed
8.
Yamaguchi H, Uchida K, Okuzumi K, Oguri T, Adachi K, Kawakami S, Tosaka M, Kawashima C, Hori Y, Kitazawa T, Hayamshi M, Saito Y, Ozaki K, Nishiyama Y: Nationwide survey of antifungal drug susceptibility of clinical fungal isolates in Japan for the Japan antifungal surveillance program (JASP), 2001–2002. J Jpn Soc Clin Microbiol. 2004, 14: 183-193.
9.
Yamaguchi H, Uchida K, Nishiyama Y, Okuizumi K, Oguri T, Adachi K, Kawakami S, Tosaka M, Misawa Y, Kawashima C, Hori Y, Kitazawa T, Hayashi M, Okimura Y: Nationwide survey of antifungal drug susceptibility of clinical fungal isolates in Japan for the Japan antifungal surveillance program (JASP), 2003. J Jpn Soc Clin Microbiol. 2006, 16: 13-22.
10.
Yamaguchi H, Nishiyama Y, Uchida K, Takahashi C, Kawashima C, Hayashi M, Kawakami S, Adachi K, Okuizumi K, Misawa Y, Oguri T, Okimura Y, Kitazawa T, Hori Y, Tosaka M: Nationwide survey of antifungal drug susceptibility of clinical fungal isolates in Japan for the Japan antifungal surveillance program (JASP), 2005. J Jpn Soc Clin Microbiol. 2009, 19: 128-141.
11.
Kamikawa Y, Nagayama T, Fujisaki J, Hirabayashi D, Kawasaki K, Hamada T, Mori Y, Kamikawa Y, Mukai H, Sato T, Sugihara K: Clinical study on anti-fungal drug activity against clinically isolated strains of oral Candida species. Oral Sci Int. 2013, 10: 87-94. 10.1016/S1348-8643(13)00006-2.CrossRef
12.
Sudo T, Makimura K, Kawata K, Ito A, Oka S, Uchida K, Yamaguchi H: Evaluation of antifungal susceptibility testing by the broth micro dilution method against Candida species: activities of 5 antifungal agents against Candida species isolated from oral candidiasis or other candidal infectious diseases and correlation of vitro data and clinical outcome of fluconazole therapy. Jpn J Chemotherapy. 1997, 45: 115-122.
13.
Kanbe T, Horii T, Arishima T, Ozeki M, Kikuchi A: PCR-based identification of pathogenic Candida species using primer mixes specific to Candida DNA topoisomerase II genes. Yeast. 2002, 19: 973-989. 10.1002/yea.892.CrossRefPubMed
14.
Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD: Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009, 48: 503-535. 10.1086/596757.CrossRefPubMed
15.
Clinical and Laboratory Standards Institute: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard-third edition M27-A3. 2008, Wayne PA USA: CLSI
16.
Yamaguchi H: Anti-fungal drug sensitivity test. Modern media. 2009, 55: 309-320.
17.
Asmundsdottir LR, Erlendsdottir H, Gottfredsson M: Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011. J Clin Microbiol. 2013, 51: 841-848. 10.1128/JCM.02566-12.CrossRefPubMedPubMedCentral
18.
de Almeida AA, Mesquita CSS, Svidzinski TIES, de Oliveira KMP: Antifungal susceptibility and distribution of Candida spp. Isolates from the university hospital in the municipality of Dourados, state of Mato Grosso do Sul, Brazil. Rev Soc Bras Med Trop. 2013, 46: 335-339. 10.1590/0037-8682-0074-2012.CrossRef
19.
De luca C, Guglielminetti M, Ferrario A, Calabrὸ M, Casari E: Candidemia: species involved, virulence factors and antimycotic susceptibility. New Microbiol. 2012, 35: 459-468.PubMed
20.
Santhanam J, Yahaya N, Aziz MN: Species distribution and antifungal susceptibility patters of Candida species: is low susceptibility to itaconazole a trend in Malaysia?. Med J Mlaysia. 2013, 68: 343-347.
21.
Pfaller M, Neofytos D, Diekema D, Azie N, Meier-Kriesche HU, Quan SP, Horn D: Epidemiology and outcomes of candidemia in 3648 patients: data from the prospective antifungal therapy (PATH alliance®) registry, 2004–2008. Diagn Microbiol Infect Dis. 2012, 74: 323-331. 10.1016/j.diagmicrobio.2012.10.003.CrossRefPubMed
22.
Moretti ML, Trabasso P, Lyra L, Fagnani R, Resende MR, de Oliveira Cardoso LG, Schreiber AZ: Is the incidence of candidemia caused by Candida glabrata increasing in Brazil? Five-year surveillance of Candida bloodstream infection in a university reference hospital in southeast Brazil. Med Mycol. 2013, 51: 225-230. 10.3109/13693786.2012.708107.CrossRefPubMed
23.
Zhang XB, Yu SJ, Yu JX, Gong YL, Feng W, Sun FJ: Retrospective analysis of epidemiology and prognostic factors for candidemia at a hospital in China, 2000–2009. Jpn J Infect Dis. 2012, 65: 510-515. 10.7883/yoken.65.510.CrossRefPubMed
24.
Hoegl L, Thoma-Greber E, Röcken M, Korting HC: Persistent oral candidosis by non-albicans Candida strains including Candida glabrata in a human immunodeficiency cirus-infected patient observed over a period of 6 years. Mycoses. 1998, 41: 335-338. 10.1111/j.1439-0507.1998.tb00347.x.CrossRefPubMed
25.
Redding SW, Kirkpatrick WR, Coco BJ, Sadkowski L, Fothergill AW, Rinaldi MG, Eng TY, Patterson TF: Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J Clin Micribiol. 2002, 40: 1879-1881. 10.1128/JCM.40.5.1879-1881.2002.CrossRef
26.
Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP: Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis. 2002, 35: 627-630. 10.1086/342300.CrossRefPubMed
27.
Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, Wagener MM, Rinaldi MG, Yu VL: The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance. Am J Med. 1996, 100: 617-623. 10.1016/S0002-9343(95)00010-0.CrossRefPubMed
28.
Pfaller AM, Jones RN, Messer SA, Edmond MB, Wenzel RP: National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. Diag Microbiol Infect Dis. 1998, 30: 121-129. 10.1016/S0732-8893(97)00192-2.CrossRef
29.
Silva S, Henriques M, Hayes A, Oliveira R, Azeredo J: Candida glabrata and Candida albicans co-infection of an in vitro oral epithelium. Oral Pathol Med. 2011, 40: 421-427. 10.1111/j.1600-0714.2010.00981.x.CrossRef
30.
Meurman JH, Siikala E, Richardson M, Rauteman R: Non-Candia albicans Candida yeasts of the oral cavity. Communicating current research and educational topics and trends in applied microbiology. 2007, Madrid: Formatex, 719-731.
31.
Sanita PV, de Oliveira Mima EG, Pavarina AC, Jorge JH, Machando AL, Vergani CE: Susceptibility profile of a Brazilian yeast stock collection of Candida species isolated form subjects with Candida-associated denture stomatitis with or without diabetes. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013, 116: 562-569. 10.1016/j.oooo.2013.07.002.CrossRefPubMed
Metadata
Title
Frequency of clinically isolated strains of oral Candida species at Kagoshima University Hospital, Japan, and their susceptibility to antifungal drugs in 2006–2007 and 2012–2013
Authors
Yoshiaki Kamikawa
Youichirou Mori
Tomohiro Nagayama
Junichi Fujisaki
Daisuke Hirabayashi
Ryoichi Sakamoto
Tomofumi Hamada
Kazumasa Sugihara
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Oral Health / Issue 1/2014
Electronic ISSN: 1472-6831
DOI
https://doi.org/10.1186/1472-6831-14-14

Other articles of this Issue 1/2014

BMC Oral Health 1/2014 Go to the issue

Research article

Reliability and validity of Arabic Rapid Estimate of Adult Literacy in Dentistry (AREALD-30) in Saudi Arabia

Research article

The prevalence, pattern and clinical presentation of developmental dental hard-tissue anomalies in children with primary and mix dentition from Ile-Ife, Nigeria

Research article

Validation of the Spanish version of the Oral Health Impact Profile (OHIP-14Sp) in elderly Chileans

Research article

Clinical validation of robot simulation of toothbrushing - comparative plaque removal efficacy

Research article

Comparing adult users of public and private dental services in the state of Minas Gerais, Brazil

Research article

Antifungal effectiveness of various intracanal medicaments against Candida albicans: an ex-vivo study